GSK2593074A is a programmed necrosis inhibitor that displays inhibitory effects on RIP1 and RIP3.

98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

DMSO:41.67 mg/mL (89.50 mM)

GSK2593074A (GSK’074) (0.01, 0.1, 1, 10, and 100 nM; 6 h) fully prevents necroptosis across various stimuli in both human and murine cells with IC50~3 nM, including MOVAS cells and L929 cells.[1]

GSK2593074A (GSK’074) (0.93 mg/kg/day; i.p.; 14 or 28 days; mice) show significantly alleviated aneurysm formation, reflected by a much smaller aortic dilatation (36.28±5.76%; P<0.05) as well as a reduced abdominal aortic aneurysm (AAA) incidence (from 83.3 to 16.7%). GSK2593074A significantly decreases the extent of aortic expansion (27.36±8.25%; P<0.05). Inhibited aneurysm formation in mouse models of aneurysms.[1]